These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 21083270)
1. Impact of matrix-associated soluble factors on the specificity of the immunogenicity assessment. Bautista AC; Wullner D; Moxness M; Swanson SJ; Chirmule N; Jawa V Bioanalysis; 2010 Apr; 2(4):721-31. PubMed ID: 21083270 [TBL] [Abstract][Full Text] [Related]
2. Unwanted immunogenicity: lessons learned and future challenges. Wadhwa M; Thorpe R Bioanalysis; 2010 Jun; 2(6):1073-84. PubMed ID: 21083209 [TBL] [Abstract][Full Text] [Related]
3. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics. Finco D; Baltrukonis D; Clements-Egan A; Delaria K; Gunn GR; Lowe J; Maia M; Wong T J Pharm Biomed Anal; 2011 Jan; 54(2):351-8. PubMed ID: 20863644 [TBL] [Abstract][Full Text] [Related]
5. Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. Lutteri L; Malaise M; Chapelle JP Clin Chim Acta; 2007; 386(1-2):76-81. PubMed ID: 17826752 [TBL] [Abstract][Full Text] [Related]
6. Proposal for a harmonized descriptive analyte nomenclature for quantitative large-molecule bioanalysis. Heinrich J; Staack RF; Stubenrauch KG; Papadimitriou A Bioanalysis; 2015 Dec; 7(24):3057-62. PubMed ID: 26505951 [No Abstract] [Full Text] [Related]
7. A novel homogeneous Biotin-digoxigenin based assay for the detection of human anti-therapeutic antibodies in autoimmune serum. Qiu ZJ; Ying Y; Fox M; Peng K; Lewin-Koh SC; Coleman D; Good J; Lowe J; Rahman A; Yang J; Jiang J; Quarmby V; Song A J Immunol Methods; 2010 Oct; 362(1-2):101-11. PubMed ID: 20868690 [TBL] [Abstract][Full Text] [Related]
8. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. Gupta S; Indelicato SR; Jethwa V; Kawabata T; Kelley M; Mire-Sluis AR; Richards SM; Rup B; Shores E; Swanson SJ; Wakshull E J Immunol Methods; 2007 Apr; 321(1-2):1-18. PubMed ID: 17307199 [TBL] [Abstract][Full Text] [Related]
9. Comparison of assay formats for drug-tolerant immunogenicity testing. Butterfield AM; Chain JS; Ackermann BL; Konrad RJ Bioanalysis; 2010 Dec; 2(12):1961-9. PubMed ID: 21110740 [TBL] [Abstract][Full Text] [Related]
10. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Smith HW; Butterfield A; Sun D Regul Toxicol Pharmacol; 2007 Dec; 49(3):230-7. PubMed ID: 17869396 [TBL] [Abstract][Full Text] [Related]
11. Development and optimization of a cell-based neutralizing antibody assay using a sample pre-treatment step to eliminate serum interference. McCutcheon KM; Quarmby V; Song A J Immunol Methods; 2010 Jun; 358(1-2):35-45. PubMed ID: 20361968 [TBL] [Abstract][Full Text] [Related]
12. Bioanalysis of biotherapeutics at a crossroad. Ezan E Bioanalysis; 2011 Mar; 3(5):469-71. PubMed ID: 21388257 [No Abstract] [Full Text] [Related]
13. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. Mire-Sluis AR; Barrett YC; Devanarayan V; Koren E; Liu H; Maia M; Parish T; Scott G; Shankar G; Shores E; Swanson SJ; Taniguchi G; Wierda D; Zuckerman LA J Immunol Methods; 2004 Jun; 289(1-2):1-16. PubMed ID: 15251407 [TBL] [Abstract][Full Text] [Related]
14. [Development of the methods for measuring drugs and their metabolites]. Ann Biol Clin (Paris); 1985; 43(4):543-57. PubMed ID: 4091315 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates. Stubenrauch K; Wessels U; Lenz H J Pharm Biomed Anal; 2009 May; 49(4):1003-8. PubMed ID: 19250787 [TBL] [Abstract][Full Text] [Related]
16. Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance. Song S; Yang L; Trepicchio WL; Wyant T J Immunol Res; 2016; 2016():3072586. PubMed ID: 27340678 [TBL] [Abstract][Full Text] [Related]
17. Detection of neutralizing interleukin-17 antibodies in autoimmune polyendocrinopathy syndrome-1 (APS-1) patients using a novel non-cell based electrochemiluminescence assay. Cludts I; Meager A; Thorpe R; Wadhwa M Cytokine; 2010 May; 50(2):129-37. PubMed ID: 20116277 [TBL] [Abstract][Full Text] [Related]
18. Detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. Wadhwa M; Gaines-Das R; Thorpe R; Mire-Sluis A Dev Biol (Basel); 2005; 122():155-70. PubMed ID: 16375260 [TBL] [Abstract][Full Text] [Related]
19. Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. Tatarewicz S; Miller JM; Swanson SJ; Moxness MS J Immunol Methods; 2010 May; 357(1-2):10-6. PubMed ID: 20347831 [TBL] [Abstract][Full Text] [Related]
20. Streamlined system for purifying and quantifying a diverse library of compounds and the effect of compound concentration measurements on the accurate interpretation of biological assay results. Popa-Burke IG; Issakova O; Arroway JD; Bernasconi P; Chen M; Coudurier L; Galasinski S; Jadhav AP; Janzen WP; Lagasca D; Liu D; Lewis RS; Mohney RP; Sepetov N; Sparkman DA; Hodge CN Anal Chem; 2004 Dec; 76(24):7278-87. PubMed ID: 15595870 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]